912893-81-3

Basic information

• Product Name: 2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-4-(4-methoxy-benzylcarbamoyl)-butyric acid
• Synonyms: 2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-4-(4-methoxy-benzylcarbamoyl)-butyric acid
• CAS NO: 912893-81-3
• Molecular Weight: 396.4
• Mol File: 912893-81-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-4-(4-methoxy-benzylcarbamoyl)-butyric acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-4-(4-methoxy-benzylcarbamoyl)-butyric acid(912893-81-3)
• EPA Substance Registry System: 2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-4-(4-methoxy-benzylcarbamoyl)-butyric acid(912893-81-3)

Safety Data

• Hazardous Substances Data: 912893-81-3(Hazardous Substances Data)

Upstream product

• 2393-23-9 4-methoxy-benzylamine 
• 3343-28-0 N-phthaloylglutamic acid anhydride 
• 6349-98-0 N-phthalylglutamic acid 

Downstream Products

• 222713-09-9 1-(4-methoxy-benzyl)-3-(1-oxo-3-phenylsulfanyl-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione 
• 222713-08-8 3-(1-hydroxy-3-oxo-1,3-dihydro-isoindol-2-yl)-1-(4-methoxy-benzyl)-piperidine-2,6-dione 
• 222713-10-2 1-(4-methoxybenzyl)-3-(1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione 
• 26581-81-7 3-(1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione 
• 222713-07-7 2-[1-(4-methoxybenzyl)-2,6-dioxopiperidin-3-yl]isoindoline-1,3-dione 

Relevant articles and documents

Thalidomide metabolites and analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNFα-modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine

Versatile synthesis of the teratogenic, TNFα-modulatory, and antiangiogenic thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine (1) and its direct antiangiogenic properties are described. With thalidomide or thalidomide derivatives as precursors, the synthesis involved either carbonyl reduction/thiation-desulfurization or carbonyl reduction/acyliminium ion reduction protocols. Compared to earlier studies with thalidomide, which was only active with microsomal treatment, 1 exhibited marginal inhibitory activity in the rat aortic ring assay, thereby demonstrating the requirement for metabolic activation.